Literature DB >> 11487371

Relationships between the prevalence and intensity of Loa loa infection in the Central province of Cameroon.

M Boussinesq1, J Gardon, J Kamgno, S D Pion, N Gardon-Wendel, J P Chippaux.   

Abstract

Ivermectin treatment may induce marked adverse effects in those harbouring > 8000 Loa microfilariae (mff)/ml of blood, individuals with > 30 000 Loa mff/ml being at risk of developing serious neurological reactions. It is thus necessary to delineate the geographical areas where such responses may occur. To determine if the simple measure of prevalence of Loa microfilaraemia would be appropriate to identify the communities at risk, the relationships between prevalence and intensity of Loa microfilaraemia were investigated in 67 villages in Cameroon. The prevalence recorded in the adult population was found to be closely related to each of the indicators of infection intensity investigated. For example, when the prevalences of Loa microfilaraemia in adults were 20%, 30% and 40%, approximately 5%, 9% and 16% of the adults had microfilarial loads exceeding 8000 mff/ml, respectively; the corresponding percentages of adults with > 30 000 mff/ml were about 1%, 3% and 5%-6%. Thus it seems that, in areas where loiasis is co-endemic, the monitoring procedure during large-scale ivermectin treatments for the control of onchocerciasis only needs to be strengthened in those communities where the prevalence of Loa microfilaraemia in adults exceeds 20%.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11487371     DOI: 10.1080/00034980120073184

Source DB:  PubMed          Journal:  Ann Trop Med Parasitol        ISSN: 0003-4983


  25 in total

1.  Analysis of the mdr-1 gene in patients co-infected with Onchocerca volvulus and Loa loa who experienced a post-ivermectin serious adverse event.

Authors:  Catherine Bourguinat; Joseph Kamgno; Michel Boussinesq; Charles D Mackenzie; Roger K Prichard; Timothy G Geary
Journal:  Am J Trop Med Hyg       Date:  2010-07       Impact factor: 2.345

2.  Potential Role for Flubendazole in Limiting Filariasis Transmission: Observations of Microfilarial Sensitivity.

Authors:  Maeghan O'Neill; Jelil Abdel Njouendou; Michael Dzimianski; Erica Burkman; Patrick Chouna Ndongmo; Jonas A Kengne-Ouafo; Samuel Wanji; Andrew Moorhead; Charles D Mackenzie; Timothy G Geary
Journal:  Am J Trop Med Hyg       Date:  2018-01       Impact factor: 2.345

3.  Community-directed delivery of doxycycline for the treatment of onchocerciasis in areas of co-endemicity with loiasis in Cameroon.

Authors:  Samuel Wanji; Nicholas Tendongfor; Theolbald Nji; Mathias Esum; Julious N Che; Armand Nkwescheu; Fifen Alassa; Geremy Kamnang; Peter A Enyong; Mark J Taylor; Achim Hoerauf; David W Taylor
Journal:  Parasit Vectors       Date:  2009-08-27       Impact factor: 3.876

4.  Case Report: Probable Case of Spontaneous Encephalopathy Due to Loiasis and Dramatic Reduction of Loa loa Microfilariaemia with Prolonged Repeated Courses of Albendazole.

Authors:  Divine B Arrey-Agbor; Hugues C Nana-Djeunga; Aude E Mogoung-Wafo; Mirabelle Mafo; Christian Danwe; Joseph Kamgno
Journal:  Am J Trop Med Hyg       Date:  2018-05-03       Impact factor: 2.345

5.  Epidemiology of concomitant infection due to Loa loa and Mansonella perstans in Gabon.

Authors:  Jean Paul Akue; Dieudonné Nkoghe; Cindy Padilla; Ghislain Moussavou; Hubert Moukana; Roger Antoine Mbou; Benjamin Ollomo; Eric Maurice Leroy
Journal:  PLoS Negl Trop Dis       Date:  2011-10-11

6.  The geographic distribution of Loa loa in Africa: results of large-scale implementation of the Rapid Assessment Procedure for Loiasis (RAPLOA).

Authors:  Honorat Gustave Marie Zouré; Samuel Wanji; Mounkaïla Noma; Uche Veronica Amazigo; Peter J Diggle; Afework Hailemariam Tekle; Jan H F Remme
Journal:  PLoS Negl Trop Dis       Date:  2011-06-28

7.  Validation of the rapid assessment procedure for loiasis (RAPLOA) in the Democratic Republic of Congo.

Authors:  Samuel Wanji; Dowo O Akotshi; Maurice N Mutro; Floribert Tepage; Tony O Ukety; Peter J Diggle; Jan H Remme
Journal:  Parasit Vectors       Date:  2012-02-02       Impact factor: 3.876

8.  The Mectizan Donation Program - highlights from 2005.

Authors:  Mary M Alleman; Nana A Y Twum-Danso; Björn I Thylefors
Journal:  Filaria J       Date:  2006-09-27

9.  Possible pathogenic pathways in the adverse clinical events seen following ivermectin administration to onchocerciasis patients.

Authors:  Charles D Mackenzie; Timothy G Geary; John A Gerlach
Journal:  Filaria J       Date:  2003-10-24

10.  Ivermectin treatment in humans for reducing malaria transmission.

Authors:  Dziedzom K de Souza; Rebecca Thomas; John Bradley; Clemence Leyrat; Daniel A Boakye; Joseph Okebe
Journal:  Cochrane Database Syst Rev       Date:  2021-06-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.